BUY Sun Pharmaceutical Industries Ltd. — Emkay Global
byEmkay GlobalHorizon: NA (inferred 1 year)6 Nov 2025via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Sun Pharma has received approval to manufacture and market semaglutide in Brazil, indicating a potential market expansion and new product offering.
BSE · Company Update·29 Jul · today
3 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · same horizon·29 Jul · yesterday
2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·27 Jul · 3d ago
Sun Pharma announced that Organon shareholders have approved the proposed acquisition, moving forward the company's strategic expansion plans.
BSE · Company Update·24 Jul · 6d ago
Sun Pharmaceutical Industries advances Tuesday, outperforms market
NewsGoogle News·21 Jul · 1w ago
Nothing found in this tip’s window yet.
Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan
NewsGoogle News·23 Jul · 1w ago
Indian pharma stocks fall after Trump outlines tariffs on generics
NewsGoogle News·22 Jul · 1w ago
Sun Pharmaceutical Industries falls Friday, outperforms competitors
NewsGoogle News·17 Jul · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Sun Pharmaceutical Industries
- BUY — HSBC Securities7 Oct 2026 · ~1 year · target ₹2,100 · Active
- SELL — Rajesh Palviya, Axis Securities5 Oct 2026 · ~3 months · target ₹1,720 · SL hit
- BUY — Sumeet Bagadia, Choice Broking29 Sept 2026 · Same day · target ₹1,875 · Expired
- BUY — 360 One Capital29 Sept 2026 · ~1 year · target ₹2,250 · Active
- BUY — Kotak Securities29 Sept 2026 · ~1 year · target ₹2,150 · Active
More from Emkay Global
- BUY Eternal22 Oct 2026 · ~1 year · target ₹420 · Active
- BUY Piramal Finance21 Oct 2026 · ~1 year · target ₹2,100 · Active
- BUY Urban Company19 Oct 2026 · ~1 year · target ₹200 · Active
- BUY ICICI Bank19 Oct 2026 · ~1 year · target ₹1,785 · Active
- BUY Ujjivan Small Finance Bank19 Oct 2026 · ~1 year · target ₹90 · Active

